as on October 14, 2025 at 8:38 pm IST
Day's Low
Day's High
0.98%
Downside
0.45%
Upside
52 Week's Low
52 Week's High
32.91%
Downside
6.00%
Upside
Check Royalty Pharma Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$21.0B
EPS (TTM)
4.445
Dividend Yield
2.79%
Quarterly Earnings Growth YOY
-0.69%
PE Ratio (TTM)
15.72
Industry PE ratio
19.200384615384614
PEG Ratio
2.7801
EBITDA
1.5B
Revenue (TTM)
2.3B
Profit Margin
44.28%
Return On Equity TTM
17.29%
Track how Royalty Pharma Plc P/E has moved over time to understand its valuation trends.
Royalty Pharma Plc in the last 5 years
Lowest (5.79x)
December 31, 2023
Today (15.72x)
October 14, 2025
Industry (19.20x)
October 14, 2025
Highest (18.03x)
March 31, 2021
Today’s Price to Earnings Ratio: 15.72x
Compare market cap, revenue, PE, and other key metrics of Royalty Pharma Plc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $21.0B | -17.18% | 15.72 | 44.28% | |
BUY | $60.3B | 223.08% | -505.15 | -12.96% | |
NA | $37.8B | NA | NA | -3.89% | |
BUY | $104.6B | 50.07% | 28.98 | 31.86% | |
BUY | $59.8B | -7.17% | 14.23 | 31.37% |
The Royalty Pharma Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Royalty Pharma Plc investment value today
Current value as on today
₹1,34,401
Returns
₹34,401
(+34.4%)
Returns from Royalty Pharma Plc Stock
₹28,633 (+28.63%)
Dollar Returns*
₹5,768 (+5.77%)
Based on 14 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Royalty Pharma Plc. Average target price of $44.5
Get share price movements and forecasts by analysts on Royalty Pharma Plc.
What analysts predicted
19.44%UPSIDE
Target Price
$44.5
Current Price
$35.85
Analyzed by
14 Analysts
Target
$44.50
Royalty Pharma Plc target price $44.5, a slight upside of 19.44% compared to current price of $35.85. According to 14 analysts rating.
Search interest for Royalty Pharma Plc Stock has increased by 5% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:5% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 30 September
Tue, 08:56 PM
-Goldman Sachs initiates coverage of Royalty Pharma with a Buy recommendation and a price target of $44.31/share.
Wed, 01:50 AM
-Royalty Pharma to announce Q3 2025 results on November 5, 2025, amid royalty disputes and expected revenue declines.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Revenue is up for the last 2 quarters, 568.24M → 578.66M (in $), with an average increase of 1.8% per quarter
Price Rise
In the last 1 year, RPRX stock has moved up by 27.2%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 150.6% return, outperforming this stock by 165.0%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 64.1% return, outperforming this stock by 36.9%
Profit Down
Netprofit is down for the last 2 quarters, 238.34M → 30.17M (in $), with an average decrease of 87.3% per quarter
Organisation | Royalty Pharma Plc |
Headquarters | 110 East 59th Street, New York, NY, United States, 10022 |
Industry | Health Technology |
CEO | Mr. Pablo Gerardo Legorreta |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. George Grofik C.F.A., CPA | Senior VP and Head of Investor Relations & Communications |
Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments |
Mr. Ashwin Pai M.D. | Executive Vice President of Investments |
Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer |
Mr. Christopher Hite | Vice Chairman & Executive VP |
Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel |
Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer |
Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & CEO |
Mr. Terrance P. Coyne | Executive VP & CFO |
Mr. George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer |
Royalty Pharma Plc share price today is $35.85 as on . Royalty Pharma Plc share today touched a day high of $36.01 and a low of $35.5.
Royalty Pharma Plc share touched a 52 week high of $38 on and a 52 week low of $24.05 on . Royalty Pharma Plc stock price today i.e. is trending at $35.85,which is 5.66% down from its 52 week high and 49.06% up from its 52 week low.
Royalty Pharma Plc market capitalisation is $0.02T as on .
Indian investors can start investing in Royalty Pharma Plc (RPRX) shares with as little as ₹88.771 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.71 in Royalty Pharma Plc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Royalty Pharma Plc share’s latest price of $35.85 as on October 14, 2025 at 8:38 pm IST, you will get 0.2789 shares of Royalty Pharma Plc. Learn more about
fractional shares .
Royalty Pharma Plc stock has given -17.18% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?